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Introduction
In phase II clinical trials in oncology, the potential efficacy of a new treatment regimen is assessed in terms of anticancer activity. The standard approach consists of a single-arm design; that is, all patients are treated with the new regimen. The endpoint of interest is typically tumor response with the possible outcomes "yes" or "no". For ethical and economical reasons, the trials are performed with planned interim analyses allowing for an early decision about stopping or continuing the development of the treatment if the number of observed responses is too low or already high enough, respectively. In practice, most trials are based on one interim analysis dividing the trial into two stages.
The most popular of such designs are still those proposed by Simon (1989) . The course of those trials can be described as follows: In the first stage of the trial, a predefined number of patients is enrolled. If the number of observed responses is too low regarding a prespecified critical value, the trial is stopped and the treatment is considered inefficient. Otherwise, another fixed number of patients is enrolled in the trial. Again the number of observed responses is examined, and the treatment is considered inefficient if the total number of observed responses is too low compared with a prespecified critical value. Because the actual sample size is a random variable and cannot be fixed in advance, different criteria can be defined regarding maximum sample size and expected sample size leading to different designs. Two criteria are given by Simon c 2011 StataCorp LP st0227 C. U. Kunz and M. Kieser 241 (1989) : determination of designs with either the minimal total sample size for the whole trial (minimax design) or the minimal expected sample size given that the null hypothesis is true (optimal design). Jung et al. (2004) introduced the admissible designs that are compromises between the minimax and the optimal designs.
Various methodological extensions of this design have been proposed, for example, by applying alternative optimality criteria (see, for example, Chang et al. [1987] , Shuster [2002] , and Mander and Thompson [2010] ). Instead of two stages (that is, one interim analysis) as in Simon's design, Chen (1997) implemented three stages. Furthermore, designs are proposed that use two endpoints (see, for example, Bryant and Day [1995] ; Lin and Chen [2000] ; Panageas et al. [2002] ; Lu, Jin, and Lamborn [2005] ; Lin, Allred, and Andrews [2008] ; and Kunz and Kieser [forthcoming] ). Other extensions can be found, for example, in Lin and Shih (2004) or Green and Dahlberg (1992) .
A limitation of minimax, optimal, and admissible designs is that early stopping can only occur at the interim analysis; stopping can occur neither before termination of the first stage nor during the second stage, even when it becomes evident that rejection of the null hypothesis can no longer be achieved. Based on the conditional power (CP)-that is, the probability of rejecting H 0 : p ≤ p 0 after the second stage under the alternative H a : p = p 1 given the results observed so far- Ayanlowo and Redden (2007) implemented stochastic curtailment rules in the second stage of the trial. Their approach was extended by Kunz and Kieser (2011) , who implemented nonstochastic (that is, when the CP is zero) and stochastic curtailment rules in both stages of the trial.
A Stata command (simon2stage) for calculating the critical values and sample sizes for the minimax and the optimal Simon's two-stage design was written by Adrian Mander (Mander 2009 ).
This article introduces another command for sample-size calculation for two-stage designs. This command, called simontwostage, allows determination of the critical values and sample sizes for the minimax, optimal, and admissible designs with or without nonstochastic or stochastic curtailment rules.
2 Two-stage designs with and without curtailment rules
Minimax and optimal designs
The objective of Simon's two-stage design is to test whether a new treatment should be developed any further. To allow for early stopping if the treatment is ineffective-that is, if the response rate p is less than or equal to a prespecified value, p 0 -an interim analysis is performed after n 1 enrolled patients. Only if more than r 1 responses are observed will the trial continue to the second stage with further n − n 1 patients. At the end of the second stage, the null hypothesis H 0 : p ≤ p 0 will be rejected if more than r responses out of n enrolled patients are observed. The critical values r 1 and r, as well as the sample sizes n 1 and n, can be determined for a specific level p 1 of the response rate in the alternative hypothesis H a .
Let b (n, x, p) denote the binomial distribution, and let B (n, x, p) denote the cumulative binomial distribution. For prespecified response levels p 0 and p 1 , the actual type I error rate α ′ and the actual type II error rate β ′ can be calculated for any given parameter set (r 1 , n 1 , r, n) in the following way:
The probability of early termination (PET) and the expected sample size (EN) if the treatment is inefficient are given by
The minimax design is defined as the design with the smallest total sample size n. If there is more than one design with smallest total sample size n, then the one with the smallest EN (p 0 ) is chosen within the possible minimax designs. The optimal design is defined as the design with the smallest EN (p 0 ) (Simon 1989).
Admissible designs
Sometimes designs can be found to fulfill the constraints regarding type I and type II errors even when those designs are neither minimax nor optimal but lie between the two regarding total sample size and EN. Those designs have a higher total sample size than the minimax design but a smaller total sample size than the optimal design. Furthermore, the EN of those designs is less than the EN of the minimax design but still higher than the EN of the optimal design. Those designs are candidates for an admissible design as defined by Jung et al. (2004) . A design is admissible when it minimizes the Bayes risk
In general, a design is admissible for a range of q. The range can be found by plotting the Bayes risk ρ against the weight q for every design found for prespecified values of p 0 , p 1 , α, and β (see figure 1 ). For each design, the slope of the line is given by n − EN (p 0 ), and the intercept is given by EN (p 0 ). The range for q for every design can be found by determining the points of intersection of the lines. Between two points of intersection, the design with the lowest Bayes risk is admissible. For q ∈ [0, 0.186], design 1 minimizes ρ and is, therefore, admissible in this range of q; for q ∈ [0.186, 0.377], design 2 is admissible; for q ∈ [0.377, 0.659], design 4 is admissible; and for q ∈ [0.659, 1], design 5 is admissible. Although there is another design (design 3), it never minimizes ρ for any given q. Therefore, it is not an admissible design.
Algorithm for determining critical values and sample sizes
The critical values and sample sizes for the minimax, optimal, and admissible designs are determined using an algorithm that searches over n, n 1 , r 1 , and r. Using (2), the smallest possible values for n and n 1 can be calculated. Because both parts of the sum of (2) are positive, any given parameter set (r 1 , n 1 , r, n) must fulfill (5):
Observing
for every given parameter set (r 1 , n 1 , r, n). If the inequality does not hold, we stop the search over r and continue with the next r 1 . Otherwise, type I and type II error rates are calculated. The algorithm continues to search over n 1 with a final value for n 1 of n − 1 until the first design is found that fulfills the constraints for type I and type II errors. From the definitions of the minimax, optimal, and admissible designs, we know that if there is more than one design with minimal total sample size, the minimax design is the one with the smallest EN within those designs. Furthermore, we know that the EN of any admissible design must be smaller than the EN of the minimax design. And finally, the optimal design has a smaller EN than any admissible design. Therefore, we know that (4), we know that for all designs n 1 < EN (p 0 ). Combining both inequalities, we know that n 1 for the admissible design must be smaller than EN (p 0 ) for the minimax design and that n 1 for the optimal design must be smaller than EN (p 0 ) for the admissible design. Therefore, the algorithm searches over n 1 up to an end value of n − 1 until the first design is found. The end value for n 1 is then replaced by EN (p 0 ) of the first design. Whenever another design is found, the end value for n 1 is replaced with the smallest EN found so far.
Nonstochastic and stochastic curtailment
Based on the CP, nonstochastic and stochastic curtailment procedures allow stopping a trial whenever it becomes evident that rejection of the null hypothesis is impossible or that the probability of rejecting the null hypothesis is lower than a prespecified cutoff value, respectively. Ayanlowo and Redden (2007) implemented stochastic curtailment rules in the second stage of Simon's design. Their approach was extended by Kunz and Kieser (2011) who implemented nonstochastic and stochastic curtailment rules in both stages of the trial. The CP of rejecting the null hypothesis under the alternative H a : p = p 1 if the trial would continue until termination of the second stage and if k responses are observed for the first n patients, 0 ≤ n ≤ n, is given by
For given n ≤ n, let k denote the maximum number of responses with CP e k,e n = 0. If k does not exist, the probability of early termination under the null hypothesis with n patients when applying nonstochastic curtailment PET e n (p0) is zero. If k exists, PET e n (p0) is given by
The expected sample size under the null hypothesis is given by
PET e n (p 0 ) × n where α ′ denotes the attained level of significance of the uncurtailed design.
While Simon's minimax and optimal designs and Jung's admissible designs are based on only two decision rules (r 1 /n 1 and r/n), curtailed designs have r + 1 decision rules, which can be determined as follows: for every s in the range of [0, r] we search over m in the range of [0, n] until the CP is less than a prespecified cutoff value c. The decision rule is given by s/ m, where m denotes the smallest m for which CP e s,m < c.
The simontwostage command
The simontwostage command calculates the critical values and sample sizes for phase II oncology trials based on Simon's two-stage design. It allows choice among the minimax, optimal, and admissible designs-with or without curtailment rules. A scatterplot of those designs similar to the scatterplots of Jung et al. (2004) can be generated.
Syntax
3.2 Options p0(#) specifies the response rate under H 0 . The response rate is a value between 0 and 1. The default is p0(0.1).
p1(#) specifies the response rate under H a . The response rate is a value between 0 and 1. Furthermore, p1() must be greater than p0(). The default is p1(0.3).
alpha(#) specifies the significance level. The default is alpha(0.05).
beta(#) specifies the limit for the type II error rate. The default is beta(0.05).
design(minimax | optimal | admissible | all) specifies the design for which the sample size is determined. Simon's (1989) minimax and optimal designs can be calculated using design(minimax) and design(optimal), respectively. Admissible design (Jung et al. 2004 ) can be obtained using design(admissible). A table containing the results of all three designs can be generated using design(all).
minn(#) specifies the start value for the total sample size. The default is minn(-1).
In this case, the minimal possible sample size will be calculated as described above.
maxn(#) specifies the end value for the total sample size. The default is maxn(-1). In this case, an end value for the total sample size is calculated.
plot generates a scatterplot based on the approach of Jung et al. (2004) . This option may be specified only if design(all) is also specified.
curtailment(# | all , reps(#) ) specifies the cutpoint for the CP. If curtailment(0) is specified, nonstochastic curtailment rules will be implemented in both stages of the trial. Type I error, type II error, EN (p0), and PET (p 0 ) for the end of the first stage and for every decision rule are calculated based on Kunz and Kieser (2011) . Therefore, reps() could not be specified. For all other values of the cutpoint, stochastic curtailment rules will be implemented in both stages of the trial, and the values are determined using simulation studies. The number of replications can be specified using the reps() option; the default is reps(1000). The decision rules are saved in a matrix. For the minimax, optimal, and admissible designs, the results are saved in r(M), r(O), and r(A), respectively. If curtailment(all , reps(#) ) is specified, all cutpoints from 0 to 1 in steps of 0.01 will be implemented. Results will be shown only for every fifth step, but all results will be saved in the matrix r(SC). Additionally, four plots will be generated. The plots show the results for the EN, the probability of early termination at the end of the first stage, the type I error, and the power, depending on the cutpoint. Gray bands show 95% confidence intervals (CIs).
weight(#) specifies the weight for the admissible design by Jung et al. (2004) . The default is weight(0.5).
Saved results
simontwostage saves the following in r():
Scalars r(minn) minimum for total sample size as finally used by Mata r(maxn) maximum for total sample size as finally used by Mata minimax r(r1 m) critical value for the first stage r(n1 m) sample size for the first stage r(r m) critical value for the end of the trial r(n m) total sample size r(en0 m) EN(p0) r(pet0 m)
PET (p0) sample size for the first stage r(r a) critical value for the end of the trial r(n a) total sample size r(en0 a) EN(p0) r(pet0 a) PET(p0) at the end of the first stage r(tie a) type I error rate r(tiie a) type II error rate if option curtailment() is specified r(cp min) minimal possible CP for the specified design r(en nsc) EN(p0) for the nonstochastic curtailed design r(en sc) EN(p0) for the stochastic curtailed design r(en sc l) lower boundary of 95% CI for EN(p0) for the stochastic curtailed design r(en sc u) upper boundary of 95% CI for EN(p0) for the stochastic curtailed design r(pet sc) PET(p0) at the end of the first stage for the stochastic curtailed design r(pet sc l) lower boundary of 95% CI for PET(p0) at the end of the first stage for the stochastic curtailed design r(pet sc u) upper boundary of 95% CI for PET(p0) at the end of the first stage for the stochastic curtailed design r(tie sc) type I error rate for the stochastic curtailed design r(tie sc l) lower boundary of 95% CI for type I error rate for the stochastic curtailed design r(tie sc u) upper boundary of 95% CI for type I error rate for the stochastic curtailed design r(tiie sc) type II error rate for the stochastic curtailed design r(tiie sc l) lower boundary of 95% CI for type II error rate for the stochastic curtailed design r(tiie sc u) upper boundary of 95% CI for type II error rate for the stochastic curtailed design Matrices r(M) stopping rules and PET(p0) for the minimax design r(O) stopping rules and PET(p0) for the optimal design r(A) stopping rules and PET(p0) for the admissible design r(C) CP for every possible outcome that can be observed during the study r(R) critical values, sample sizes, EN, PET(p0), type I error, type II error, interval for weight r(SC) cutpoint for CP, EN, PET(p0), type I error, type II error, lower and upper limits for the 95% CI
Use of simontwostage
In this section, the use of simontwostage will be explained. Let us consider that we want to plan a phase II trial in oncology. We assume that the response rate under H 0 is p 0 ≤ 0.05. The new treatment is considered efficient if the response rate under H a is p 1 > 0.25. Furthermore, we choose a significance level of α = 0.05 and a power of 1 − β = 0.90. As a first step, we use the following command:
. simontwostage, p0(0.05) p1(0.25) alpha(0.05) beta(0.10) design(all) plot
Simon´s Two Stage Design
This algorithm is searching for the minimax, optimal, and admissible design for the following parameter specifications As can be seen in the output, five designs fulfilling the prespecified constraints for p 0 , p 1 , α, and β are found. The first one is Simon's minimax design, the second and the fourth ones are admissible designs according to Jung et al. (2004) , and the last one is Simon's optimal design (see figure 2) . The third design is neither minimax nor admissible nor optimal.
The first column gives the critical value and the sample size for the first stage for each design. For example, the critical value and the sample size for the first stage for the minimax design are 0 and 15, respectively. The second column gives the critical value and the sample size for the whole trial. For the minimax designs, these are 3 and 25. The third and the fourth columns give the EN under H 0 [see (4)] and the probability of early termination under H 0 [see (3)]. The next two columns give the actual type I and type II errors [see (1) and (2)]. And the last column gives the range for the weight q as defined by Jung et al. (2004) . In the plot, the first admissible design with n = 26 and EN (p 0 ) = 18.43 is marked. The default value for the weight() option is 0.5, which is in the interval of [0.377, 0.659] . Because no other value was specified in the command, the corresponding admissible design is marked in the plot.
Let us assume that we want to use the second admissible design with n = 28 and EN (p 0 ) = 17.22 for our study. We therefore have to specify the weight() option with any value between [0.186, 0.377] . In the next step, we use the following command to determine the effect of implementing curtailment rules (also see figure 3 ):
. simontwostage, p0(0.05) p1(0.25) alpha(0.05) beta(0.10) design(admissible) > weight(0.3) curtailment(all, reps (10000) Figure 3 . Plots based on 10,000 replications generated with the curtailment(all, reps(10000)) option. Gray areas mark 95% CIs.
The first row in the output Using matrix list r(A), we obtain the new decision rules. We now have four decision rules-(0/10), (1/22), (2/25), and (3/28)-instead of the two decision rules for the uncurtailed admissible design. But we also have a smaller EN, and furthermore, the curtailed design allows for early stopping after the end of the first stage but before the end of the second stage. For example, the cumulative probability of early termination if the treatment is ineffective with 22 enrolled patients is 0.5913 + 0.1737 = 0.765. C. U. Kunz and M. Kieser 253 
Summary
This article described a new Stata command for calculating the critical values and sample sizes for Simon's minimax, Simon's optimal, and Jung's admissible designs. The command also implements nonstochastic and stochastic curtailment rules in both stages of the trial and allows comparison of the resulting designs with those of the uncurtailed designs.
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